302 related articles for article (PubMed ID: 30954880)
1. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.
Kacew AJ; Harris EJ; Lorch JH; Haddad RI; Chau NG; Rabinowits G; LeBoeuf NR; Schmults CD; Thakuria M; MacConaill LE; Hanna GJ
Eur J Cancer; 2019 May; 113():1-9. PubMed ID: 30954880
[TBL] [Abstract][Full Text] [Related]
2. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
[TBL] [Abstract][Full Text] [Related]
3. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
5. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
Redon R; Muller D; Caulee K; Wanherdrick K; Abecassis J; du Manoir S
Cancer Res; 2001 May; 61(10):4122-9. PubMed ID: 11358835
[TBL] [Abstract][Full Text] [Related]
6. Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic Markers.
Gupta R; Strbenac D; Satgunaseelan L; Cheung VK; Narayanappa H; Ashford B; Mitchell J; Thind A; Palme CE; Ch'ng S; Low TH; Wykes J; Willet CE; Chew T; Yang J; Ranson M; Clark JR
Mod Pathol; 2023 Aug; 36(8):100190. PubMed ID: 37080394
[TBL] [Abstract][Full Text] [Related]
7. Advanced Cutaneous Squamous Cell Carcinoma: Italian Multicentric Retrospective Analysis of Patient Profiles and Therapeutic Approaches.
Mannino M; Piccerillo A; Dika E; Vaccari S; Quaglino P; Rubatto M; Longo C; Borsari S; Pellacani G; Fargnoli MC; Caponio C; Argenziano G; Briatico G; Bianchi L; Di Raimondo C; Calzavara Pinton PG; Zalaudek I; Di Stefani A; Peris K
Dermatology; 2023; 239(3):422-428. PubMed ID: 36921583
[TBL] [Abstract][Full Text] [Related]
8. Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?
Zilberg C; Lee MW; Kraitsek S; Ashford B; Ranson M; Shannon K; Iyer NG; Ch'ng S; Low TH; Palme C; Clark J; Gupta R; Yu B
J Clin Pathol; 2020 Jan; 73(1):17-22. PubMed ID: 31300530
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
Kim EY; Ruiz ES; DeSimone MS; Shalhout SZ; Hanna GJ; Miller DM; Schmults C; Rettig EM; Foreman RK; Sethi R; Thakuria M; Silk AW
JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):414-420. PubMed ID: 38546619
[TBL] [Abstract][Full Text] [Related]
10. Targeted deep sequencing reveals genomic alterations of actinic keratosis/cutaneous squamous cell carcinoma in situ and cutaneous squamous cell carcinoma.
Kim YS; Jung SH; Park YM; Park GS; Kim HS; Maeng LS; Chung YJ
Exp Dermatol; 2023 Apr; 32(4):447-456. PubMed ID: 36533870
[TBL] [Abstract][Full Text] [Related]
11. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
13. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Mutational and Phenotypic Characterization of New Metastatic Cutaneous Squamous Cell Carcinoma Cell Lines Reveal Novel Drug Susceptibilities.
Perry J; Ashford B; Thind AS; Gauthier ME; Minaei E; Major G; Iyer NG; Gupta R; Clark J; Ranson M
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333825
[TBL] [Abstract][Full Text] [Related]
15. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
Lee A; Duggan S; Deeks ED
Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
[TBL] [Abstract][Full Text] [Related]
16. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
[TBL] [Abstract][Full Text] [Related]
17. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
Ahmed SR; Petersen E; Patel R; Migden MR
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
[No Abstract] [Full Text] [Related]
18. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
[TBL] [Abstract][Full Text] [Related]
19. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
Venkatesh S; Al-Haseni A; Sahni D
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718
[TBL] [Abstract][Full Text] [Related]
20. Cemiplimab in advanced cutaneous squamous cell carcinoma.
Naik PP
Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
